MaxCyte, Inc. License with Sana Biotechnology (9261H)
August 09 2021 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9261H
MaxCyte, Inc.
09 August 2021
MaxCyte Signs Clinical and Commercial License with Sana
Biotechnology
Agreement represents MaxCyte's 14(th) strategic platform license
(SPL)
Sana will use MaxCyte's Flow Electroporation (R) technology and
ExPERT(TM) platform in conjunction with the development of its
hypoimmune cell therapy programs
GAITHERSBURG, MD, 9 August 2021 - MaxCyte, Inc. (Nasdaq: MXCT)
(LSE: MXCT, MXCN), a leading provider of cell-engineering platform
technologies, today announced the signing of a clinical and
commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA) , a
company focused on creating and delivering engineered cells as
medicines.
Under the terms of the agreement, Sana Biotechnology obtains
non-exclusive clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related milestone payments.
Doug Doerfler, President and CEO of MaxCyte, said: "We are
delighted to support Sana's ex vivo cell therapy programs and
recognize the potential of the company's novel hypoimmune cell
platform to advance treatments for serious diseases. This agreement
represents an important achievement for MaxCyte as we continue to
expand the use of our next-generation technology platform to
support the development of innovative treatments."
MaxCyte's ExPERT instrument portfolio represents the next
generation of leading, clinically-validated, electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics.
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform
technologies to advance innovative cell-based research, development
and potential commercialization of next-generation cell therapies.
The Company's existing customer base ranges from large
biopharmaceutical companies - including 20 of the top 25
pharmaceutical companies based on 2020 global revenue - to hundreds
of biotechnology companies and academic translational centers.
MaxCyte has granted 14 strategic platform licenses to commercial
cell therapy developers that allow for more than 75 clinical
programs. Founded in 1998, MaxCyte is headquartered in
Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black / Duncan Monteith / Matthew O'Dowd +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams +44 (0)20 7710 7600
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
US Media Relations +1 410-299-3310
Jamie Lacey-Moreira jamielacey@presscommpr.com
PressComm PR, LLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCQVLFBFVLZBBK
(END) Dow Jones Newswires
August 09, 2021 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024